What is Cetrorelix?

An FDA-approved GnRH antagonist used in IVF to prevent a premature LH surge.

Cetrorelix in the library · · Human Trials · What are peptides?

70 registered trials · 124 indexed papers · 247 human / 31 animal studies

From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.

What it is

Cetrorelix (Cetrotide) is described as a decapeptide that blocks GnRH receptors, quickly lowering LH and FSH. It is used during controlled ovarian stimulation.

Mechanism (as described)

Unlike GnRH agonists such as leuprolide, it suppresses hormones immediately without an initial flare.

Evidence (as described)

It is well established in reproductive medicine (Findeklee et al., 2023) and has been studied for fibroids and endometrial thinning (Bhatia et al., 2008).

Status

FDA-approved (Cetrotide).

Registered human trials (70)

Trial	Phase	Status	Year	Enrolled
A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)	Phase 3	recruiting	2026	266
Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A	Phase 3	not yet recruiting	2026	204
Trial Comparing Subcutaneous Natural Progesterone (Prolutex) vs. Cetrorelix Acetate for Luteinizing Hormone Surge Suppression in Freeze-All IVF Cycles.	Phase 4	not yet recruiting	2026	230
Oral GnRH Antagonist (Linzagolix) Versus Injectable GnRH Antagonist in Controlled Ovarian Stimulation for In Vitro Fertilization: A Randomized Controlled Non-Inferiority Trial With a Concurrent Comparator Cohort Undergoing Progestin-Primed Ovarian Stimulation (PPOS)		not yet recruiting	2026	120
Drospirenone-Primed Ovarian Stimulation Versus GnRH Antagonist Protocol in Poor Ovarian Responders Undergoing Freeze-All IVF/ICSI	Phase 1/Phase 2	not yet recruiting	2026	100
Progesterone Primed Protocol Versus GnRH Antagonist in With PCO Undergoing ICSI	Phase 2/Phase 3	completed	2024	200
Effectiveness of Generic Versus Reference Cetrorelix Acetate for Ovarian Stimulation Using a Gonadotropin-releasing Hormone（GnRH）Antagonist Protocol in Women Undergoing IVF		recruiting	2024	1338
PPOS vs GnRH Antagonist in Ovarian Stimulation (ProGanOS Study)		active not recruiting	2024	626
Can Drospirenone be Used to Prevent LH Surge in Controlled Ovarian Stimulation in PCOS?!	Phase 1/Phase 2	completed	2024	50
Dydrogesterone, Cetrorelix Acetate and Triptorelin in Intra Cytoplasmic Sperm Injection Outcomes	Phase 3	unknown	2023	387
Acupuncture in the Freeze-all IVF Cycle		unknown	2023	90
Efficacy and Safety of BG2109 During Controlled Ovarian Hyperstimulation in Female Subjects Undergoing ART Procedures	Phase 2	unknown	2023	240
Dydrogesterone-Primed Ovarian Stimulation Protocol Versus Gonadotropin Releasing Hormone Antagonist Protocol in ICSI		unknown	2023	79
Progesterone Primed Ovarian Stimulation Versus GnRH Antagonist Protocols in Women With Polycystic Ovarian Syndrome		completed	2023	100
PPOS Protocol Versus GnRH Anatagonist for Expected Normal Responder Patients Undergoing ART : a Randomized Clinical Trial	Phase 3	completed	2023	328
Progestin-primed Ovarian Stimulation Protocol Versus GnRH Antagonist Protocol in Polycystic Ovary Syndrome Patients Undergoing IVF/ICSI Cycles		unknown	2021	200
Testosterone and Neurovascular Control in Humans		unknown	2021	20
Sequential Therapy of TCM Herbs to Improve the Success Rate of IVF-ET in Diminished Ovarian Reserve Patients	Phase 3	unknown	2021	200
Traditional Chinese Medicine Herbs in the Freeze-all IVF Cycle	Phase 3	unknown	2021	90
GnRH Antagonist Pre-treatment in the Early Follicular Phase for Resolution of a Baseline Functional Ovarian Cyst	Phase 4	unknown	2021	15
Progesterone-Primed Ovarian Simulation in Controlled-ovarian Simulation of Infertile PCOS Patients		completed	2021	238
Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology During IVF/ICSI	Phase 4	completed	2020	50
Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology in Polycystic Ovary Syndrome Patients During IVF/ICSI	Phase 4	completed	2020	50
Comparison of the Live Birth Rate Between the PPOS and the GnRH Antagonist Protocol in Patients Undergoing IVF		terminated	2020	220
Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Patients Undergoing PGT-A	Phase 3	completed	2020	400
Live Birth Rate Between PPOS and GnRH Antagonist Protocol in Patients With Anticipated High Ovarian Response	Phase 3	completed	2020	784
Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes.	Phase 4	completed	2019	50
Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes in Polycystic Ovary Syndrome Patients.	Phase 4	completed	2019	50
Comparison Between Two Different Protocols in Polycystic Ovary Symdrome Women Undergoing Intra-cytoplasmic Injection	Phase 4	unknown	2019	150
Coasting Versus Antagonist Protocol in Patients at High Risk of OHSS	Phase 4	completed	2019	300
Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.		completed	2019	44
Efficacy of Growth Hormone Supplementation With Gonadotrophins in IVF/ICSI for Poor Responders	Phase 4	completed	2018	156
Frozen Embryo Transfer With GnRH-antagonist Trial	Phase 4	unknown	2018	300
Long Protocol and Freeze All Embryos vs Antagonist Protocol With Fresh Embryo Transfer in PCOS Patients Undergoing ICSI	Phase 4	completed	2017	204
Cetrorelix and Ganirelix Flexible Protocol for (IVF)	Phase 4	unknown	2017	100
Patients' Preference for Subcutaneous or Vaginal Progesterone as Luteal Support in IVF/ICSI Cycles	Phase 4	terminated	2016	60
The Impact of Body Weight on Reproductive Outcomes in Poor Ovarian Responders in ICSI Cycles		unknown	2015	185
Delayed Start Versus Conventional Antagonist Protocol in Poor Responders Pretreated by Estradiol in Luteal Phase	Phase 3	completed	2015	60
Luteal Antagonist Versus Conventional Treatment in Women With Severe Early Ovarian Hyperstimulation Syndrome (OHSS)		unknown	2015	40
Dysregulation of FSH in Obesity: Functional and Statistical Analysis		completed	2015	99

Peer-reviewed studies (124)

Paper	Authors	Journal	Year	Type
Cocktail treatment by GnRH-antagonist, letrozole, and mifepristone for the prevention of ovarian hyperstimulation syndrome: a prospective randomized trial	Qi Q et al.	Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology	2023	Randomized Controlled Trial
Medroxyprogesterone Acetate versus Gonadotropin-Releasing Hormone Antagonist for the Prevention of Premature Luteinizing Hormone Surge in hyper-responder women undergoing controlled ovarian stimulation for IVF/ICSI Cycles	Tandulwadkar S et al.	JBRA assisted reproduction	2023	Randomized Controlled Trial
[Letrozole versus gonadotropin-releasing hormone antagonist during luteal phase in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial]	Cheng ZX et al.	Zhonghua fu chan ke za zhi	2020	Randomized Controlled Trial
NAV3, a Tumor Suppressor Gene, Is Decreased in Uterine Leiomyoma Tissue and Cells	Aly JM et al.	Reproductive sciences (Thousand Oaks, Calif.)	2020	Randomized Controlled Trial
Mild Versus Conventional Ovarian Stimulation for Poor Responders Undergoing IVF/ICSI	Siristatidis C et al.	In vivo (Athens, Greece)	2017	Randomized Controlled Trial
Clinical experience with an ovarian stimulation protocol for intrauterine insemination adopting a gonadotropin releasing hormone antagonist at low dose	Ponzano A et al.	Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology	2017	Controlled Clinical Trial
GnRH antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial	Fouda UM et al.	Journal of ovarian research	2016	Randomized Controlled Trial
Rapid Anti-Inflammatory Effects of Gonadotropin-Releasing Hormone Antagonism in Rheumatoid Arthritis Patients with High Gonadotropin Levels in the AGRA Trial	Kåss A et al.	PloS one	2015	Randomized Controlled Trial
Low-dose human chorionic gonadotropin adjunct to an antagonist protocol in assisted reproductive technology: a randomized trial study	Aghahosseini M et al.	Acta medica Iranica	2014	Randomized Controlled Trial
Quantitative serial MRI of the treated fibroid uterus	Munro KI et al.	PloS one	2014	Randomized Controlled Trial
Short-term treatment with a gonadotropin-releasing hormone antagonist, cetrorelix, in rheumatoid arthritis (AGRA): a randomized, double-blind, placebo-controlled study	Kåss AS et al.	Scandinavian journal of rheumatology	2014	Randomized Controlled Trial
The addition of GnRH antagonists in intrauterine insemination cycles: a pilot study	Graziano A et al.	European review for medical and pharmacological sciences	2013	Controlled Clinical Trial
Cost-effectiveness comparison between pituitary down-regulation with a gonadotropin-releasing hormone agonist short regimen on alternate days and an antagonist protocol for assisted fertilization treatments	Maldonado LG et al.	Fertility and sterility	2013	Randomized Controlled Trial
Effect of the gonadotropin-releasing hormone antagonist cetrorelix on the prevention of chemotherapy-induced ovarian damage in women with hematological malignancy	Digeni A et al.	International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics	2012	Clinical Trial
GnRH-agonist versus GnRH-antagonist IVF cycles: is the reproductive outcome affected by the incidence of progesterone elevation on the day of HCG triggering? A randomized prospective study	Papanikolaou EG et al.	Human reproduction (Oxford, England)	2012	Randomized Controlled Trial
Administration of a gonadotropin-releasing hormone antagonist to mares at different times during the luteal phase of the estrous cycle	Evans MJ et al.	Animal reproduction science	2011	Clinical Trial
Cetrorelix suppresses the preovulatory LH surge and ovulation induced by ovulation-inducing factor (OIF) present in llama seminal plasma	Silva ME et al.	Reproductive biology and endocrinology : RB&E	2011	Randomized Controlled Trial
Effectiveness of a low gonadotrophin-releasing hormone antagonist dose in preventing premature luteinizing hormone rise during controlled ovarian stimulation	Tiboni GM et al.	Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology	2011	Randomized Controlled Trial
Effects of cetrorelix, a GnRH-receptor antagonist, on gonadal axis in women with functional hypothalamic amenorrhea	Berardelli R et al.	Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology	2011	Controlled Clinical Trial
Cetrorelix lowers premature luteinization rate in gonadotropin ovulation induction-intrauterine insemination cycles: a randomized-controlled clinical trial	Steward RG et al.	Fertility and sterility	2011	Randomized Controlled Trial
Fixed versus flexible gonadotropin-releasing hormone antagonist administration in in vitro fertilization: a randomized controlled trial	Kolibianakis EM et al.	Fertility and sterility	2011	Randomized Controlled Trial
Dose-ranging study of the luteinizing hormone-releasing hormone receptor antagonist cetrorelix pamoate in the treatment of patients with symptomatic benign prostatic hyperplasia	Debruyne F et al.	Urology	2010	Randomized Controlled Trial
Comparison of gonadotropin-releasing hormone agonists and antagonists in assisted reproduction cycles of polycystic ovarian syndrome patients	Hosseini MA et al.	The journal of obstetrics and gynaecology research	2010	Randomized Controlled Trial
Randomized, comparative pilot study of pituitary suppression with depot leuprorelin versus cetrorelix acetate [amount hidden] in gonadotropin stimulation protocols for oocyte donors	Martínez F et al.	Fertility and sterility	2010	Randomized Controlled Trial
Safety and efficacy of mixing cetrorelix with follitropin alfa: a randomized study	Lin YH et al.	Fertility and sterility	2010	Randomized Controlled Trial
High doses of GnRH antagonists are efficient in the management of severe ovarian hyperstimulation syndrome	Bonilla-Musoles FM et al.	Clinical and experimental obstetrics & gynecology	2009	Clinical Trial
[Long GnRH agonist vs. GnRH antagonist protocol in randomized controlled trial in unselected patients--hormonal and cycle characteristics--pilot study]	Streda R et al.	Ceska gynekologie	2009	Randomized Controlled Trial
Cessation of gonadotropin-releasing hormone antagonist on triggering day: an alternative method for flexible multiple-dose protocol	Chang HJ et al.	Journal of Korean medical science	2009	Controlled Clinical Trial
Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial	Galindo A et al.	Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology	2009	Randomized Controlled Trial
Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle	Kahraman K et al.	Fertility and sterility	2009	Randomized Controlled Trial

More cited research

Conditions researched

Related compounds

FAQ

What is Cetrorelix?

An FDA-approved GnRH antagonist used in IVF to prevent a premature LH surge.

How many registered human trials study Cetrorelix?

The PeptideWhiz trial index lists 70 registered trials for Cetrorelix, the most recent from 2026.

How much published research exists on Cetrorelix?

The PeptideWhiz paper index links 124 PubMed papers to Cetrorelix; by study type, 247 human and 31 animal studies.

Which conditions is Cetrorelix researched for?

Anti-aging & longevity, Endometriosis, Fat loss, obesity & body recomposition, Female fertility, Insulin resistance, prediabetes & type 2 diabetes, Male fertility and sperm, Menopause & perimenopause, PCOS, Pregnancy and breastfeeding: safety notes, Prostate inflammation, Rheumatoid arthritis.

Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).